Search research articles
Contact Us
Filters
Showing results (61-70 of 939) with videos related to
Page
of 94
Sort By:
BJU International
|
March 24, 2018
Molecular model for neuroendocrine prostate cancer progression
Ruiqi Chen, Xuesen Dong, Martin Gleave
Communicable Disease and Public Health
|
June 20, 2002
What is needed on a laboratory test request form?
J Hopwood, T Gleave, H Mallinson
Molecular Urology
|
June 14, 2000
Immunohistochemical Analysis of Radical Prostatectomy Specimens After 8 Months of Neoadjuvant Hormonal Therapy
Paterson, Gleave, Jones, et al.
The Journal of Organic Chemistry
|
September 6, 1996
Oxazolidinone Antibacterial Agents. An Enantioselective Synthesis of the [6,5,5] Tricyclic Fused Oxazolidinone Ring System and Application to the Synthesis of a Rigid DuP 721 Analogue
D. Mark Gleave, Steven J. Brickner
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer
Amina Zoubeidi, Kim Chi, Martin Gleave
Cancer Chemotherapy and Pharmacology
|
November 8, 2005
Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer
Martin Gleave, Hideaki Miyake, Kim Chi
Applied Biochemistry and Biotechnology
|
July 1, 1991
Growth inhibition in animal cell culture. The effect of lactate and ammonia
T Hassell, S Gleave, M Butler
Current Opinion in Urology
|
February 7, 2013
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer
Joseph Ischia, Fred Saad, Martin Gleave
Histopathology
|
January 4, 2012
Targeted therapy in prostate cancer
Niall M Corcoran, Martin E Gleave
European Urology
|
October 23, 2010
Words of wisdom. Re: comparative effectiveness of minimally invasive versus open radical prostatectomy
Anthony J Koupparis, Martin E Gleave
Page
of 94
Search research articles
Search
Showing results (61-70 of 939) with videos related to
Sort By:
Page
of 94
BJU International
|
March 24, 2018
Molecular model for neuroendocrine prostate cancer progression
Ruiqi Chen, Xuesen Dong, Martin Gleave
Communicable Disease and Public Health
|
June 20, 2002
What is needed on a laboratory test request form?
J Hopwood, T Gleave, H Mallinson
Molecular Urology
|
June 14, 2000
Immunohistochemical Analysis of Radical Prostatectomy Specimens After 8 Months of Neoadjuvant Hormonal Therapy
Paterson, Gleave, Jones, et al.
The Journal of Organic Chemistry
|
September 6, 1996
Oxazolidinone Antibacterial Agents. An Enantioselective Synthesis of the [6,5,5] Tricyclic Fused Oxazolidinone Ring System and Application to the Synthesis of a Rigid DuP 721 Analogue
D. Mark Gleave, Steven J. Brickner
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2010
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer
Amina Zoubeidi, Kim Chi, Martin Gleave
Cancer Chemotherapy and Pharmacology
|
November 8, 2005
Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer
Martin Gleave, Hideaki Miyake, Kim Chi
Applied Biochemistry and Biotechnology
|
July 1, 1991
Growth inhibition in animal cell culture. The effect of lactate and ammonia
T Hassell, S Gleave, M Butler
Current Opinion in Urology
|
February 7, 2013
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer
Joseph Ischia, Fred Saad, Martin Gleave
Histopathology
|
January 4, 2012
Targeted therapy in prostate cancer
Niall M Corcoran, Martin E Gleave
European Urology
|
October 23, 2010
Words of wisdom. Re: comparative effectiveness of minimally invasive versus open radical prostatectomy
Anthony J Koupparis, Martin E Gleave
Page
of 94